Hillcrest Energy Technologies Ltd.: Hillcrest ZVS Technology Demonstrates More Than 90% Reduction in Motor Voltage Spikes

Hillcrest Energy Technologies announced peer-reviewed test results showing its ZVS inverter technology reduces motor voltage overshoot by over 90% and high-frequency EMI by up to 25 dB compared to conventional SiC inverters. The findings were accepted for presentation at the IEEE ECCE 2026 conference.

Original reporting
Published Sep 29, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 1:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$HLRTF
Relevance
4/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

Low
01

Why it matters

The announcement provides technical validation but does not include commercial contracts or revenue guidance.

02

Market read

Technical breakthrough with limited immediate trading relevance; primarily of interest to niche industrial investors.

03

What to watch

The need for extensive validation in real‑world drive systems and the competitive landscape of SiC inverter suppliers.

Relevance 4/10Novelty 5/10Timing: none

Background

Hillcrest Energy Technologies announced peer‑reviewed test results for its zero‑voltage‑switching inverter, showing >90% reduction in motor voltage overshoot and lower EMI.

Market effects

Demonstrates a potential efficiency gain for the power‑electronics and industrial automation sector, but impact is limited to niche OEMs.

Primarily relevant to North American and European drive‑system manufacturers; no broad market effect.

Low; the technology is early‑stage and the company is micro‑cap.

Counterpoint

Even with impressive lab results, commercial adoption may be slow and the market may discount the news.

Key entities

  • Hillcrest Energy Technologies Ltd.

    Micro‑cap power‑electronics firm (CSE:HEAT, OTCQB:HLRTF).

  • Dr. Emanuel Serban

    Vice President of Engineering, presented the paper at IEEE ECCE 2026.

Related articles

$HLRTFMed

Hillcrest Energy Technologies Signs Letter of Intent with Equipmake to Integrate ZVS Technology into Electric Powertrain Platform

Hillcrest Energy Technologies (CSE:HEAT, OTCQB:HLRTF, FRA:7HI) said it signed a non-binding July 7, 2026 letter of intent with Equipmake plc to jointly develop and integrate Hillcrest’s Zero Voltage Switching inverter technology into a defined Equipmake powertrain line. Hillcrest cites 99.7% peak inverter efficiency and up to 6% system gains, plus lower EMI in testing. The LOI is milestone-gated for up to 24 months and includes RSU grants of 117,647 units.

$HLRTFMed

Hillcrest Energy Technologies Ltd.: Hillcrest Announces Closing of Non-brokered Private Placement of Units

Hillcrest Energy Technologies (CNSX: HEAT; OTCQB: HLRTF; FSE: 7HI) said it has closed its non-brokered private placement of 7,968,319 units at $0.15 per unit, raising gross proceeds of $1,195,247.85. Each unit includes a common share and a warrant exercisable at $0.20 for 24 months. Proceeds will be used for payables retirement, advisors/consultants, and working capital.

$HOODHigh

Robinhood to allow 24-hour weekend trading of US stocks as industry shifts to wider access

Robinhood announced plans to allow 24-hour weekend trading for select US stocks and ETFs, pending regulatory approval. The move follows the company's 2023 introduction of extended weekday trading, which accounted for up to 25% of daily volume. Robinhood also plans to offer earnings-based bets and perpetual futures, along with AI-driven trading tools. SEC Chair Paul Atkins supports extended trading hours for real-time market reactions.

$LLYHighAI 9/10

Eli Lilly (LLY) Reports Strong TRIUMPH-2 Trial Results for Retat

Eli Lilly (LLY) reported positive Phase 3 trial results for retatrutide, showing significant weight loss and improved glycemic control in type 2 diabetes patients. The company plans an FDA submission by Q1 2027. LLY's stock is modestly undervalued, with a GF Value™ of $1,559.98, 24.1% above its current price of $1,184.63. The GF Score™ is 96/100, indicating strong financial health and growth.